Last reviewed · How we verify
varicella-5
Varicella-5 is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection.
Varicella-5 is a live attenuated varicella-zoster virus vaccine that stimulates immune responses to prevent chickenpox infection. Used for Prevention of varicella (chickenpox) in susceptible individuals.
At a glance
| Generic name | varicella-5 |
|---|---|
| Sponsor | Changchun Keygen Biological Products Co., Ltd. |
| Drug class | Live attenuated vaccine |
| Target | Varicella-zoster virus |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains a weakened strain of varicella-zoster virus that replicates in host cells but does not cause disease in immunocompetent individuals. This triggers both humoral (antibody) and cell-mediated immune responses, providing protective immunity against natural varicella-zoster virus infection. The attenuated virus induces long-lasting immunity that prevents or significantly reduces the severity of chickenpox.
Approved indications
- Prevention of varicella (chickenpox) in susceptible individuals
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Fever
- Rash
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- varicella-5 CI brief — competitive landscape report
- varicella-5 updates RSS · CI watch RSS
- Changchun Keygen Biological Products Co., Ltd. portfolio CI